18-Month Retrospective Claims Analysis Study Information on Ruxolitinib
April 7th 2025Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.
Read More
Results and Takeaways From a 12-month Claims Analysis of Ruxolitinib
March 31st 2025Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, reduced rescue medication use, fewer dermatology visits, and a favorable safety profile compared to standard treatments, supporting its role as a valuable non-steroidal topical option for long-term management.
Read More
Key Background Information on Atopic Dermatitis
March 17th 2025Panelists discuss how atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and recurring eczematous lesions, affects millions worldwide, with complex genetic and environmental factors influencing its development, progression, and treatment response.
Read More
Navigating Insurance Barriers in Atopic Dermatitis
May 28th 2024An expert on the treatment of atopic dermatitis provides insights on navigating insurance barriers and discusses how managed care organizations can incentivize and support the implementation of evidence-based guidelines and best practices across healthcare settings.
Read More
Treatment Decisions and the Role of Systemic Therapy in Atopic Dermatitis
May 28th 2024An expert dermatologist outlines factors that influence treatment selection for patients with atopic dermatitis and discusses how often patients need systemic therapy, given the available topical therapy options.
Read More